美国生物製药第三方物流市场规模、份额、趋势分析报告：依供应链、服务、产品、细分市场预测，2025-2030年

美国生物製药第三方物流市场成长及趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，美国生物製药第三方物流市场规模将达到874.4亿美元，2025年至2030年复合年增长率为7.56%，预计将达到这一水平。

对新型生技药品的需求不断增长以及管理它们的需求正在推动市场成长。对跨不同地区运输生技药品的温控物流服务的需求不断增加，以及生物製药公司扩大分销网络以提高销售，也推动了成长。

由于航空货运能力下降以及仓库和机场劳动力减少，COVID-19大流行在一定程度上对全球物流产生了重大影响。地方政府的决定，例如关闭物流基础设施、实施行动限制以及提出额外要求以抑制病毒传播，也正在影响物流服务。这对许多供应业务造成了严重干扰。

在美国，政府对运输和就地避难的监管正在逐步放鬆，生物製药第三方物流行业的未来看起来一片光明。疫情期间，低温运输物流需求激增。预计 2021 年 COVID-19 疫苗的生产和分销将出现成长。例如，2021 年 3 月，联邦快递开始将 McKesson Corp. 的 COVID-19 疫苗运送到美国各地的中心。自 2020 年 12 月中旬以来，该公司已发货数百万支 COVID-19 疫苗。

美国生物製药第三方物流市场亮点

• 低温运输物流板块销售占比最大，2024年为58.39%。该细分市场主要是由不需要严格温度控制的标准生物药品的分销推动的，从而允许扩大运输和储存选择。
• 2024年，仓储业将主导市场。该部门整合了自动化仓储和即时库存管理等高科技系统，为温度敏感和非温度敏感产品提供专门的储存解决方案。
• 预计到 2024 年，特种药品领域将占据市场最大的收益占有率，并在估计期间呈现最高的复合年增长率。这是由于这些高价值且通常对温度敏感的药品具有独特的处理要求。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章美国生物製药第三方物流（3PL）市场变数、趋势与范围

• 市场体系展望
  • 母市场展望
  • 配套市场前景
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 技术景观
• 定价模式分析
• 产业生态系统分析
• 市场分析工具
  • 波特五力分析
  • PESTEL分析
  • COVID-19 影响分析

第四章美国生物製药第三方物流市场：供应链估算及趋势分析

• 细分仪表板
• 生医第三方物流市场：供应链波动分析
• 2018-2030年美国生物製药第三方物流（3PL）市场估计与预测
• 低温运输
• 非低温运输

第五章美国生物製药第三方物流市场：服务评估与趋势分析

• 细分仪表板
• 生物製药第三方物流市场：服务变化分析
• 2018-2030年美国生物製药第三方物流（3PL）市场估计与预测
• 运输
  • 空运
  • 海运
  • 陆运
• 仓储
• 其他的

第六章美国生物製药第三方物流市场：产品估算与趋势分析

• 细分仪表板
• 生物製药第三方物流市场：产品变异分析
• 2018-2030年美国生物製药第三方物流（3PL）市场估计与预测
• 特种药品
• 非专利的
• 血浆衍生产品
• 其他的

第七章 竞争格局

• 公司分类
  • 市场领导者
  • 新兴企业
• 公司市场分析
• 公司简介
  • UPS Healthcare
  • Cardinal Health
  • KUEHNE+NAGEL
  • AmerisourceBergen Corp.
  • McKesson Corporation
  • Thermo Fisher Scientific
  • DHL International GmbH
  • DB Schenker
  • Kerry Logistics Network Ltd.
  • CEVA Logistics
  • Agility Logistics
  • SF Express
  • XPO Logistics
  • Cencora, Inc.
  • EVERSANA

U.S. Biopharmaceutical Third-party Logistics Market Growth & Trends:

The U.S. biopharmaceutical third-party logistics market size is estimated to reach USD 87.44 billion by 2030, registering to grow at a CAGR of 7.56% from 2025 to 2030 according to a new report by Grand View Research, Inc. Increasing demand for novel biologics and the need to manage those is boosting the market growth. Besides, rising demand for temperature-controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales are factors driving the growth.

The COVID-19 pandemic has had a major impact on global logistics to some extent due to diminished air freight capacity and reduced workforce at warehouses and airports. The decisions of local authorities to shut down the logistic infrastructure, enforce movement restrictions, or put in place additional requirements to suppress transmission of the virus have also impacted the logistic services. This has significantly hindered many supply operations.

The future seems lucrative for the biopharmaceutical third-party logistics industry in the U.S. with the retraction of government regulations related to transportation and shelter-in-place mandates. A sudden surge in the demand for cold chain logistics was observed during the pandemic. Growth in the manufacture and distribution of the COVID-19 vaccine is expected throughout 2021. For instance, in March 2021, FedEx Express started shipping COVID-19 vaccines for McKesson Corp. to centers all across the U.S. The company has already shipped millions of COVID-19 vaccines since mid-December 2020.

U.S. Biopharmaceutical Third-party Logistics Market Highlights

• The non-cold chain logistics segment accounted for the largest revenue share of 58.39% in 2024. The segment is primarily driven by the distribution of standard biopharmaceutical products that do not require stringent temperature control, allowing for a broader range of transportation and storage options.
• The warehousing and storage segment dominated the market in 2024. This segment provides specialized storage solutions for both temperature-sensitive and non-sensitive products, integrating high-tech systems such as automated warehouses and real-time inventory management.
• The specialty drugs segment accounted for the largest revenue share in the market in 2024 and is expected to witness the highest CAGR over the estimated timeline. This is attributed to the unique handling requirements of these high-value, often temperature-sensitive medications.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Estimates and forecast timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Industry Ecosystem Analysis
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. U.S. Biopharmaceutical Third-Party Logistics Market: Supply Chain Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Biopharmaceutical Third-Party Logistics Market: Supply Chain Movement Analysis
• 4.3. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 4.4. Cold Chain
  • 4.4.1. Cold Chain Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 4.5. Non-Cold Chain
  • 4.5.1. Non-Cold Chain Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. U.S. Biopharmaceutical Third-Party Logistics Market: Service Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Biopharmaceutical Third-party Logistics Market: Service Movement Analysis
• 5.3. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.4. Transportation
  • 5.4.1. Transportation Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4.2. Air Freight
    • 5.4.2.1. Air Freight Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4.3. Sea Freight
    • 5.4.3.1. Sea Freight Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4.4. Overland Transportation
    • 5.4.4.1. Overland Transportation Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.5. Warehousing & Storage
  • 5.5.1. Warehousing & Storage Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.6. Others
  • 5.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. U.S. Biopharmaceutical Third-Party Logistics Market: Product Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Biopharmaceutical Third-Party Logistics Market: Product Movement Analysis
• 6.3. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.4. Specialty Drugs
  • 6.4.1. Specialty Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.5. Generics
  • 6.5.1. Generics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.6. Plasma Derived Products
  • 6.6.1. Plasma Derived Products Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.7. Others
  • 6.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
  • 7.1.1. Market Leaders
  • 7.1.2. Emerging Players
• 7.2. Company Market Position Analysis
• 7.3. Company Profiles
  • 7.3.1. UPS Healthcare
    • 7.3.1.1. Company Overview
    • 7.3.1.2. Financial Performance
    • 7.3.1.3. Service Benchmarking
    • 7.3.1.4. Strategic Initiatives
  • 7.3.2. Cardinal Health
    • 7.3.2.1. Company Overview
    • 7.3.2.2. Financial Performance
    • 7.3.2.3. Service Benchmarking
    • 7.3.2.4. Strategic Initiatives
  • 7.3.3. KUEHNE + NAGEL
    • 7.3.3.1. Company Overview
    • 7.3.3.2. Financial Performance
    • 7.3.3.3. Service Benchmarking
    • 7.3.3.4. Strategic Initiatives
  • 7.3.4. AmerisourceBergen Corp.
    • 7.3.4.1. Company Overview
    • 7.3.4.2. Financial Performance
    • 7.3.4.3. Service Benchmarking
    • 7.3.4.4. Strategic Initiatives
  • 7.3.5. McKesson Corporation
    • 7.3.5.1. Company Overview
    • 7.3.5.2. Financial Performance
    • 7.3.5.3. Service Benchmarking
    • 7.3.5.4. Strategic Initiatives
  • 7.3.6. Thermo Fisher Scientific
    • 7.3.6.1. Company Overview
    • 7.3.6.2. Financial Performance
    • 7.3.6.3. Service Benchmarking
    • 7.3.6.4. Strategic Initiatives
  • 7.3.7. DHL International GmbH
    • 7.3.7.1. Company Overview
    • 7.3.7.2. Financial Performance
    • 7.3.7.3. Service Benchmarking
    • 7.3.7.4. Strategic Initiatives
  • 7.3.8. DB Schenker
    • 7.3.8.1. Company Overview
    • 7.3.8.2. Financial Performance
    • 7.3.8.3. Service Benchmarking
    • 7.3.8.4. Strategic Initiatives
  • 7.3.9. Kerry Logistics Network Ltd.
    • 7.3.9.1. Company Overview
    • 7.3.9.2. Financial Performance
    • 7.3.9.3. Service Benchmarking
    • 7.3.9.4. Strategic Initiatives
  • 7.3.10. CEVA Logistics
    • 7.3.10.1. Company Overview
    • 7.3.10.2. Financial Performance
    • 7.3.10.3. Service Benchmarking
    • 7.3.10.4. Strategic Initiatives
  • 7.3.11. Agility Logistics
    • 7.3.11.1. Company Overview
    • 7.3.11.2. Financial Performance
    • 7.3.11.3. Service Benchmarking
    • 7.3.11.4. Strategic Initiatives
  • 7.3.12. SF Express
    • 7.3.12.1. Company Overview
    • 7.3.12.2. Financial Performance
    • 7.3.12.3. Service Benchmarking
    • 7.3.12.4. Strategic Initiatives
  • 7.3.13. XPO Logistics
    • 7.3.13.1. Company Overview
    • 7.3.13.2. Financial Performance
    • 7.3.13.3. Service Benchmarking
    • 7.3.13.4. Strategic Initiatives
  • 7.3.14. Cencora, Inc.
    • 7.3.14.1. Company Overview
    • 7.3.14.2. Financial Performance
    • 7.3.14.3. Service Benchmarking
    • 7.3.14.4. Strategic Initiatives
  • 7.3.15. EVERSANA
    • 7.3.15.1. Company Overview
    • 7.3.15.2. Financial Performance
    • 7.3.15.3. Service Benchmarking
    • 7.3.15.4. Strategic Initiatives

List of Tables

• Table 1. List of Secondary Sources
• Table 2. List of Abbreviations
• Table 3. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market by Supply Chain, 2018 - 2030 (USD Billion)
• Table 4. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market by Service, 2018 - 2030 (USD Billion)
• Table 5. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market by Product, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 Biopharmaceutical Third-Party Logistics, Market Segmentation
• Fig. 7 Market Driver Analysis (Current & Future Impact)
• Fig. 8 Market Restraint Analysis (Current & Future Impact)
• Fig. 9 Porter's Five Forces Analysis
• Fig. 10 PESTEL By SWOT Analysis
• Fig. 11 U.S. Biopharmaceutical Third-Party Logistics, for Cold Chain Logistics, 2018 - 2030 (USD Million)
• Fig. 12 U.S. Biopharmaceutical Third-Party Logistics, for Non-cold Chain Logistics, 2018 - 2030 (USD Million)
• Fig. 13 U.S. Biopharmaceutical Third-Party Logistics, for Transportation, 2018 - 2030 (USD Million)
• Fig. 14 U.S. Biopharmaceutical Third-Party Logistics, for Air Freight, 2018 - 2030 (USD Million)
• Fig. 15 U.S. Biopharmaceutical Third-Party Logistics, for Sea Freight, 2018 - 2030 (USD Million)
• Fig. 16 U.S. Biopharmaceutical Third-Party Logistics, for Overland, 2018 - 2030 (USD Million)
• Fig. 17 U.S. Biopharmaceutical Third-Party Logistics, for Warehousing and Storage, 2018 - 2030 (USD Million)
• Fig. 18 U.S. Biopharmaceutical Third-Party Logistics, for Other Services, 2018 - 2030 (USD Million)
• Fig. 19 U.S. Biopharmaceutical Third-Party Logistics, for Specialty Drugs, 2018 - 2030 (USD Million)
• Fig. 20 U.S. Biopharmaceutical Third-Party Logistics, for Generics, 2018 - 2030 (USD Million)
• Fig. 21 U.S. Biopharmaceutical Third-Party Logistics, for Plasma Derived Products, 2018 - 2030 (USD Million)
• Fig. 22 U.S. Biopharmaceutical Third-Party Logistics, for Others, 2018 - 2030 (USD Million)